Xingang Biomedical Technology

Xingang Biomedical is a clinical-stage biotechnology company headquartered in Suzhou, China, specializing in the discovery and development of innovative small molecule and antibody-based therapies for oncology. The company leverages a proprietary structure-based drug design platform to target historically "undruggable" proteins, with a primary focus on the RAS/MAPK signaling pathway. Its lead programs include highly selective inhibitors targeting KRAS mutations such as G12D and G12C, aimed at addressing significant unmet needs in lung, colorectal, and pancreatic cancers. Xingang Biomedical is committed to advancing a robust pipeline of precision medicines through internal R&D and strategic collaborations within the global biopharmaceutical ecosystem.